TCM Composition Ratios for IBS-C Constipation Relief

The patent applies parameter changes by precisely controlling the ratios of active ingredients (sennoside A, sennoside B, magnolol, paeoniflorin, albiflorin, corydaline, tetrahydropalmatine) within specific ranges (e.g., sennoside A: 0.1-5.0 mg/g, sennoside B: 0.1-5.0 mg/g). This systematic parameter optimization ensures consistent therapeutic effects while providing clear manufacturing specifications that resolve the contradiction between reliability and manufacturing precision.

The patent employs composite materials by formulating a multi-component TCM composition containing seven specific active ingredients with defined concentration ranges. This composite approach integrates multiple herbal extracts (Corydalis Rhizoma, Paeoniae Radix, Magnoliae Officinalis Cortex, Sennae Folium) into a unified formulation that achieves synergistic therapeutic effects while maintaining manufacturability through standardized composition specifications.

The patent applies universality by designing a multi-functional formulation where seven active ingredients work synergistically to address multiple aspects of constipation treatment: sennosides stimulate intestinal motility, magnolol and honokiol regulate gut-brain axis, paeoniflorin and albiflorin reduce inflammation, corydaline and tetrahydropalmatine modulate pain perception. This multi-functional approach enhances therapeutic efficacy while the standardized composition framework manages formulation complexity.

The patent manages formulation complexity through parameter changes by establishing specific concentration ranges for each of the seven active ingredients (e.g., magnolol: 0.01-1.0 mg/g, paeoniflorin: 1.0-10.0 mg/g). These defined parameters transform a potentially complex multi-ingredient formulation into a standardized, manufacturable product with consistent quality and predictable therapeutic effects.